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Verapamil, a potent calcium antagonist, possessesvaried
systemic effects, including smooth muscle relaxation
leading to both peripheral and coronary artery vasodi-
lation, slowed atrioventricular nodal conduction and de-
creased insulin release from the pancreatic B cells. Re-
ports concerning the effects of acute intoxication with
verapamil are scarce. A case is presented of a 22 year
Verapamil hydrochloride, a calcium antagonist, was intro-
duced in 1962 as a potent coronary vasodilator (1) and has
been used as an antianginal drug (2,3). It was later found
to possess definite salutory antiarrhythmic properties (4-8).
This antiarrhythmic action was originally attributed to beta-
adrenergic blockade, but has since been attributed to calcium
channel blockade at the level of the cellular membrane (8).
Reports concerning verapamil' s side effects (9-11) and
associated acute intoxication (12-19) are scarce. After acute
intoxication with verapamil, a variety of neurologic, car-
diovascular and metabolic derangements have been re-
ported, including mental confusion, hypotension, trifasci-
cular block, asystole, metabolic acidosis and hyperglycemia.
We report an unusual case of acute intoxication with ver-
apamil after a self-administered oral dose of 2,400 mg. This
case is unique in that there were profound metabolic alter-
ations, the magnitude of which have not been reported pre-
viously. Furthermore, it elucidates the inhibitory effect ver-
apamil has on the secretion of insulin.
Case Report
A 22 year old obese, nondiabetic white woman with a
past history of multiple somatic complaints referrable to the
cardiovascular system was taken to the emergency room 3
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old woman who developed profound hyperglycemia and
metabolic acidosisafter the inadvertent overdose of thirty
80 mg tablets (2,400 mg) of verapamil. This case illus-
trates the need for physicians to be aware of verapamil's
inhibitory effects on insulin release and to exercise spe-
cial care when prescribing verapamil in patients with
preexisting diabetes mellitus.
hours after the ingestion of 30 tablets of verapamil, each
containing 80 mg. She was lethargic, but responsive to
painful stimuli and loud voices. The pupils were equal and
reacted sluggishly to light. Respirations were spontaneous,
but shallow. Deep tendon reflexes were normal. The skin
was pale and cool to the touch. The systolic blood pressure
was 60 mm Hg by Doppler method and the heart rate was
30 beats/min. The electrocardiogram revealed an idioven-
tricular rhythm without evidence of atrial electrical activity.
Initial treatment. An intravenous infusion of 5% dex-
trose in normal saline solution was rapidly initiated and the
rate was kept wide open. Atropine, 0.5 mg, was given
intravenously, Subsequently, an isoproterenol infusion was
started, all without apparent effect. As the patient was known
to have been taking verapamil, she then received 2 g of
calcium chloride intravenously with continuous electrocar-
diographic monitoring. There was no beneficial effect on
heart rate and a temporary percutaneous transvenous pacing
electrode was introduced. Ventricular pacing was achieved
at a capture rate of 70/min.
Simultaneously, an endotracheal tube was inserted and
the patient received assisted ventilation. Gastric lavage was
initiated and blood, urinary and gastric contents were sent
for analysis. Hypotension persisted, necessitating the ini-
tiation of a continuous infusion of dopamine. After these
measures, the patient's blood pressure increased to approx-
imately 80 mm Hg systolic by Doppler method. Laboratory
blood test results were noted (Table 1), particularly, hy-
perkalemia, hyperglycemia and metabolic acidosis.
Clinical course. During the next several hours, the pa-
tient's sensorium progressively improved to the point where
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Table 1. Laboratory Data Obtained on Arrival at the
Emergency Room
BUN = blood urea nitrogen: Lymphs = lymphocytes, Pco- = partial
pressure of carbon dioxide: Po, = partial pressure of oxygen: Segs =
segmented neutrophils (polymorphonuclear leukocytes), Stab, = band cells
(nonsegmented polymorphonuclear leukocytes. WBC = white blood cell
she responded appropriately to simple commands. Pupillary
reflexes and urinary output improved. On receipt of the
blood glucose value of 832 mgll 00 ml, intravenous solution
was changed to normal saline solution and 5 units of regular
insulin were given intravenously. This insulin bolus was
followed by a continuous infusion of regular insulin at a
rate of 0.1 mg/kg per hour. The serum electrolytes and blood
glucose were measured hourly.
Three hours after hospitalization, serum chemistry de-
terminations revealed a blood glucose of 250 mg/IOO ml,
serum potassium of 4.0 mEq/liter and bicarbonate of
25 mEq/liter. The temporary pacemaker was turned off,
revealing a junctional rhythm at a rate of 50 beats/min.
Blood pressure had stabilized at 90 mm Hg systolic.
As the patient's condition improved, the isoproterenol,
dopamine and insulin infusions were gradually stopped. The
serum lactic acid level had returned to normal and repeat
serum acetone determination was negative. Subsequent blood
glucose determinations were all within the normal range.
On the morning after admission, all intravenous medications
were discontinued. the patient was weaned from the ven-
tilator and the temporary pacemaker was removed. The re-
mainder of the hospital course was uneventful.
The drug screen performed on blood. unnary and gastric
samples obtained at the time of admission was negative.
Blood samples were also obtained for determination of the
serum verapamil level and the blood level was found to be
845.7 ng/ml.
Blood Test
Na ' (rnliq/liter)
K' (mfiq/liter)
C 1- (mEq/liter)
CO, - (mEq/lIter)
Glucose (mgllOO mil
Lactic acid (mmolliiter)
Acetone (j.Lmol/lIter)
BUN (mg/IOO rnl)
Hemoglobin (g/IOO rnl)
WBC count (X lOJ/cmm)
Differentral count ('K)
Stabs
Segs
Lymphs
Arterial blood gases
Po, (rnm Hg)
Pco, (rnrn Hg)
pH
Hco, - (mmol/hter)
Results
130
7.2
101
16
832
45
500
17
13.1
27
I'K
85'K
14%
54
39
7.21
16
Normal Values
135 to 145
3.6 to 5.0
98 to 110
22 to 30
70 to 120
05 to 2 2
oto 500
5 to 22
12 to 16
45 to 10
83 to 108
35 to 45
7 38 to 7.42
21 to 28
Discussion
Pharmacodynamics of verapamil. Verapamil Isoptin
Calan (isopropyl N-methyl-N-homoveratryl aminopropyl-3-
4 dimethoxy-phenyl-acetonitril HCll. a potent calcium an-
tagonist. has been found to be well absorbed after oral
ingestion. Eighty percent of verapamil is absorbed between
45 minutes and 3 hours after ingestion (8). The peak plasma
concentration is reached between the first and second hour
after administration. The first pass effect through the portal
circulation causes 60 to 70% of the oral dose to be bio-
transformed; thus. bioavailability of verapamil ranges from
20 to 35%. After repeated doses at 6 hour intervals, the
half-life of verapamil increases. progressively stabilizing at
a range of 4.5 to 12.0 hours; thereafter. there is a good
linear correlation between plasma levels and the adminis-
tered verapamil dose.
Verapamil hydrochloride is water-soluble and highly pro-
tein-bound in plasma. After an oral dose. it undergoes ex-
tensive hepatic metabolism. No fewer than 12 metabolites
of verapamil have been identified in plasma. The majority
of these metabolites are present only in trace amounts and
possess little biologic activity. Approximately 70% of an
orally administered dose of verapamil is recovered from the
urine in the form of metabolites. with only about 5% of the
drug being excreted unchanged. The remainder is excreted
in the feces.
Physiologic effects. The action of verapamil is mediated
by blocking the slow channel responsible for calcium influx
in myocardial and smooth muscle cells (18.19). It has also
been shown (20) to inhibit a second slow current carried by
the sodium cation. Antagonism of the slow channels in
smooth muscle ultimately produces smooth muscle relax-
ation. This relaxation in the vascular smooth muscle cells
results in both peripheral and coronary artery vasodilation.
Electrophvsiologic studies (8) have demonstrated that
verapamil prolongs the functional and effective refractory
periods of cardiac conduction tissue and has been shown to
interfere with sinus node impulse generation. These alter-
ations in the electrophysiologic properties of cardiac muscle
cells manifest themselves clinically as slowed atrioventric-
ular (AV) conduction and negative chronotropic effect. These
effects are dose-dependent. It has been demonstrated that
high verapamil concentrations can induce sinus arrest as
well as AV block.
Toxic effect. There are relatively few reported cases of
serious adverse reactions. Bradsky et al. (II) observed he-
patocellular toxicity 4 weeks after initiation of oral therapy
with verapamil. They concluded that the hepatotoxicity was
of an idiosyncraticnature. Hypotension. advanced AV block
and asystole have been reported previously (9,21.22) in
cases of massive overdose. after aggressive intravenous
administration and when veraparml was used in combination
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with other cardiovascular drugs (beta-adrenergic blocking
agents and digitalis). The toxic effects of verapamil have
been successfully reversed by infusions of calcium chloride
and hypertonic saline solution (12,23). The potential ad-
verse cardiac electrophysiologic effects of verapamil have
been described previously by several investigators (9,10,24)
independently in patients with verapamillevels greater than
359 ng/ml. Finally, severe left ventricular dysfunction has
been associated with both acute and chronic ingestion of
verapamil hydrochloride. This effect is more pronounced in
subjects with an ejection fraction below 34% (25).
We have found only one other reference documenting
impaired carbohydrate metabolism associated with vera-
pamil, a case report by DaSilva et al. (13) in which there
was only a moderate elevation of blood glucose (344 mg/ I00
ml): this was the highest blood glucose level reported after
ingestion of verapamil; the patient was not known to be
diabetic and had experienced acute intoxication with the
drug.
Verapamil and insulin release. Our case clearly dem-
onstrates the spectrum of complications induced by a mas-
sive ingestion of verapamil. The hypotension, mental con-
fusion and metabolic acidosis occurred as a result of decreased
tissue perfusion, from both verapamil-mediated reduction
in cardiac output and peripheral vasodilation. The AV dis-
sociation can be explained by the depressant effect vera-
pamil exerts on the sinoatrial and AV nodes. Finally, the
massive hyperglycemia may be speculatively explained as
a result of the inhibitory effect verapamil has on insulin
release.
Calcium channel antagonists have been shown to affect
insulin release in vivo. The concentration of extracellular
calcium ions is known to playa crucial role in insulin release
from the pancreatic beta cells, the secretory process being
triggered by the cytosolic accumulation of calcium (26-28).
Calcium antagonists, like verapamil, are known to inhibit
in vitro glucose and sulfonylurea-induced insulin release by
interfering with calcium entry into the beta islet cells (29-32).
Several in vivo studies have also demonstrated calcium an-
tagonists' inhibitory effect on the beta islet cells of the
pancreas and subsequent insulin production. Taniguchi et
al. (33) found that the infusion of 44 mg of the calcium
antagonist, diItiazem, for 2 hours in a patient with insuli-
noma suppressed leucin-induced insulin release, while the
basal insulin level was only transiently suppressed. In the
same patient, chronic administration of diltiazem reduced
the number of hypoglycemic attacks as compared with the
pretreatment period. DeMarinis and Barbarino (34) also dis-
covered that the intravenous infusion of verapamil produced
a marked and significant inhibition of glucose, glucagon and
sulfonylurea-induced increases in serum insulin in normal
subjects. They also treated two patients with islet cell tumors
with verapamil for 5 days and discovered that these patients
experienced a decrease in the severity and frequency of
hypoglycemic attacks while antonomous insulin release was
inhibited.
Clinical implications. The clinical significance of our
observation is obvious in view of the extensive use of cal-
cium channel antagonists in modem medical practice. Much
like the use of beta-receptor blocking agents, the use of
calcium channel antagonists may continue to expand. As
experience with these drugs increases, so too will the in-
cidence of untoward effects. Just as Birnbaum et aI. (35)
found a positive correlation between therapeutic doses of
propranolol and increased glucose intolerance, in our opin-
ion, verapamil must also be regarded as diabetogenic. The
extent of deterioration of carbohydrate tolerance in patients
receiving therapeutic doses of calcium channel antagonists
remains unknown. Theoretically, however, this knowledge
could significantly influence prescribing practices.
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